BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/13/2021 10:05:39 AM | Browse: 777 | Download: 1003
 |
Received |
|
2021-01-24 03:50 |
|
Peer-Review Started |
|
2021-01-24 03:53 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-02-23 06:21 |
|
Revised |
|
2021-02-27 23:42 |
|
Second Decision |
|
2021-04-22 06:26 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2021-04-22 11:55 |
|
Articles in Press |
|
2021-04-22 11:55 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2021-04-27 08:53 |
|
Publish the Manuscript Online |
|
2021-05-13 10:05 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Risk of hepatitis B virus reactivation in patients with autoimmune diseases undergoing non-tumor necrosis factor-targeted biologics
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Shintaro Akiyama, Thomas G Cotter and Atsushi Sakuraba |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Shintaro Akiyama, MD, MSc, PhD, Academic Fellow, Doctor, Doctor, Section of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Chicago, 5841 S. Maryland Ave. MC 4076, Chicago, IL 60637, United States. akiyama_s@hotmail.co.jp |
| Key Words |
Hepatitis B virus; Autoimmune diseases; Biological therapy; Interleukin-23; Interleukin-17; Janus kinases |
| Core Tip |
Although the risk of hepatitis B virus reactivation (HBVr) in patients undergoing non-tumor necrosis factor (TNF)-targeted biologics have not been fully understood, some previous studies showed that the risk of HBVr in patients with non-TNF-targeted biologics might be higher than that in patients with TNF-α inhibitors. While patients with chronic HBV should receive antiviral prophylaxis when they start non-TNF-targeted biologics, antiviral prophylaxis may be a favorable strategy rather than the pre-emptive strategy in patients with resolved HBV. Large-scale studies are needed to ascertain the differential risk of HBVr between patients with TNF-α inhibitors and non-TNF-targeted biologics. |
| Publish Date |
2021-05-13 10:05 |
| Citation |
Akiyama S, Cotter TG, Sakuraba A. Risk of hepatitis B virus reactivation in patients with autoimmune diseases undergoing non-tumor necrosis factor-targeted biologics. World J Gastroenterol 2021; 27(19): 2312-2324 |
| URL |
https://www.wjgnet.com/1007-9327/full/v27/i19/2312.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v27.i19.2312 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
